{"id":743003,"date":"2023-03-28T07:05:19","date_gmt":"2023-03-28T11:05:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/"},"modified":"2023-03-28T07:05:19","modified_gmt":"2023-03-28T11:05:19","slug":"tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/","title":{"rendered":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)"},"content":{"rendered":"<h2>\nFDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <strong>First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease<\/strong>\n        <\/li>\n<li>\n          <strong>Tiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMS<\/strong>\n        <\/li>\n<li>\n          <strong>Phase 2 protocol to be submitted to the FDA in April<\/strong>\n        <\/li>\n<li>\n          <strong>Phase 2 clinical trial expected to start in Q3 2023<\/strong>\n        <\/li>\n<\/ul>\n<p>NEW YORK, March  28, 2023  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS. Tiziana plans to accept the FDA\u2019s recommendations and intends to start a Phase 2 study in the third quarter of 2023 as previously announced. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb).<\/p>\n<p>\u201cTiziana has reached an important regulatory milestone as it proceeds with the first ever intranasal foralumab clinical trial,\u201d commented Gabriele Cerrone, Executive Chairman and interim Chief Executive Officer. \u201cThe FDA\u2019s response to our proposed Phase 2 program allows Tiziana\u2019s to advance foralumab through the regulatory process as we strive to bring this novel treatment to patients with non-active SPMS.\u201d<\/p>\n<p>\u201cI am grateful for the FDA\u2019s thoughtful review of our Phase 2 plans for intranasal foralumab,\u201d stated Matthew W. Davis, M.D., RPh, Chief Medical Officer. \u201cThis upcoming quarter, we will update the Phase 2 protocol with the FDA\u2019s suggestions and plan to start the Phase 2 clinical trial by holding our first investigator\u2019s meeting in Q3 2023.\u201d\u00a0\u00a0<\/p>\n<p>\n        <strong>About Foralumab<\/strong>\n      <\/p>\n<p>Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.<sup>1<\/sup><\/p>\n<p>\n        <strong>About\u00a0Tiziana Life Sciences<\/strong>\n      <\/p>\n<p>Tiziana Life Sciences\u00a0is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p>For further inquiries:<\/p>\n<p>\n        <strong>Tiziana Life Sciences Ltd<\/strong>\n      <\/p>\n<p>Paul Spencer, Business Development and Investor Relations <br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YkETI6LY4sv1nf9gCKODibn1fhvIlueYyF8-P2szUnkwvepcv-ebHMl6mHKDcsxno-s35TM9r6YgfemZ3D8yu4U0A5Ny5BmBQszCxfO5IU5w65ibTzhV627SJsOHkPfIf9QoCT7bfivRIqxFlgol_f-wDFPph7cqrbHCd8Ea_vXc6LFNN1YbDT2448XF5_SWODU79tF21FDXcd5-gej-cqiTByzw_7XFJb5DH5y8d_aPLa2r9CZPuhlAURmqVPOma1GCJyBMWX-Xs6liBsRP34L8lHpIxUHhOnJsgFOh55QWXgLXUYD2RsM7c_uGrVpM1KpVEfFaArbsqPxjwzLlidSSD45SmAsgmAMkUbsmCTU97Syu9Z_sBTfydi67r-2_UnD0L6WGxzCe2UDKD4fHUkggM1QbjLdGqaT_yJ6s54DEQ8PO_mYdD8Nm6fb1z9G9WdKdL2X-9L-hT5IunTYvXIaZZUu-jFLIn4-AVB_WANCmsB_2MbcpGj6UWorbWpM24pNCQnXZOfI2vYf9YN1CdQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>info@tizianalifesciences.com<\/u><\/a><\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Irina Koffler<br \/>LifeSci Advisors, LLC<br \/>646.970.4681<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-bD_pg9lrgLW07FYu_5KOQ4097bkXMdJ1694LkL7FuxZrbc8JywZmc5vjXVU82u0y4ur_8xMSWeh8k_8X2d_j4QVDjLRq2uev0WnU88NN5YvH-f94LRWRKFvI-EdtCjQfhdEqgtrUPh8uyouV0OBNqjIXG8n7UBjfzb2IktrPtYzqUiU3MORuQwblUnn0gu64GXFyyHuHdkBA5AFPMMHYtrPNGyYMvCOjKTQJbCivw-1Iofa2I93WT7-2qeI1fpYtvJKdQNJKV-xWR2NJZjrMtEn-YAy14FTtRne3b1rJqb1d9_lERqSZpV6IGaXPzQ88Ahmc6h1bRgLGL6iG46ojPQ7hV5gErm1Aq_etQe30i70A4hW_KdbhqGNSR_qyRx5yuKMDT5F21znK3ZxcEUrxcB-scg29We3RvHFel8T8VMO3gNJ_r0Z6smQzionEna7dPYl7HpqjwN3z5Chnp_HBofE1gNjAZSEqZVhlVJPt4bTITD1OBbn-P0lPLlai90j4KUftE4RuyHO4uDlAxc_1g==\" rel=\"nofollow noopener\" target=\"_blank\"><u>ikoffler@lifesciadvisors.com<\/u><\/a><\/p>\n<p>\n        <sup>1<\/sup><br \/>\n        <sub>https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2220272120<\/sub>\n      <\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzI3ZTViYjktNjYxOS00M2Y1LWE5Y2MtOWQ5NTE5ODg2MzRkLTExMzU0NTY=\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease Tiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMS Phase 2 protocol to be submitted to the FDA in April Phase 2 clinical trial expected to start in Q3 2023 NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-743003","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease Tiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMS Phase 2 protocol to be submitted to the FDA in April Phase 2 clinical trial expected to start in Q3 2023 NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial &hellip; Continue reading &quot;Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-28T11:05:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)\",\"datePublished\":\"2023-03-28T11:05:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/\"},\"wordCount\":524,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/\",\"name\":\"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\",\"datePublished\":\"2023-03-28T11:05:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk","og_description":"FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing intranasal foralumab for treating inflammatory neurological disease Tiziana received FDA Type C Meeting Minutes for proposed Phase 2 clinical trial in patients with non-active SPMS Phase 2 protocol to be submitted to the FDA in April Phase 2 clinical trial expected to start in Q3 2023 NEW YORK, March 28, 2023 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial &hellip; Continue reading \"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-28T11:05:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)","datePublished":"2023-03-28T11:05:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/"},"wordCount":524,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/","name":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=","datePublished":"2023-03-28T11:05:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjQ4MyM1NDk0NjU0IzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-to-proceed-with-phase-2-clinical-trial-in-patients-with-non-active-secondary-progressive-multiple-sclerosis-spms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743003","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=743003"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/743003\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=743003"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=743003"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=743003"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}